Related references
Note: Only part of the references are listed.DICKKOPF-4 Activates the Noncanonical c-Jun-NH2 Kinase Signaling Pathway While Inhibiting the Wnt-Canonical Pathway in Human Renal Cell Carcinoma
Hiroshi Hirata et al.
CANCER (2011)
Targeted-Therapy in Advanced Renal Cell Carcinoma
M. T. Pirrotta et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Molecular Diagnosis and Therapy of Kidney Cancer
W. Marston Linehan et al.
ANNUAL REVIEW OF MEDICINE (2010)
miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion
Hongping Xia et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery
Patrick J. Eulitt et al.
CANCER BIOLOGY & THERAPY (2010)
MicroRNA-34a Inhibits Cell Proliferation by Repressing Mitogen-Activated Protein Kinase Kinase 1 during Megakaryocytic Differentiation of K562 Cells
Atsuhiko Ichimura et al.
MOLECULAR PHARMACOLOGY (2010)
MicroRNA control of signal transduction
Masafumi Inui et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Down-Regulation of mir-424 Contributes to the Abnormal Angiogenesis via MEK1 and Cyclin E1 in Senile Hemangioma: Its Implications to Therapy
Taiji Nakashima et al.
PLOS ONE (2010)
VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma
W. Marston Linehan et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Downregulated MicroRNA-200a in Meningiomas Promotes Tumor Growth by Reducing E-Cadherin and Activating the Wnt/β-Catenin Signaling Pathway
Okay Saydam et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
MicroRNAs as potential cancer therapeutics
P Trang et al.
ONCOGENE (2009)
Expression of cortactin and survivin in renal cell carcinoma associated with tumor aggressiveness
Giueng-Chueng Wang et al.
WORLD JOURNAL OF UROLOGY (2009)
Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma
Naomi Walsh et al.
BMC Urology (2009)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Predicting disease progression after nephrectomy for localized renal cell carcinoma: The utility of prognostic models and molecular biomarkers
Paul L. Crispen et al.
CANCER (2008)
miRDB: A microRNA target prediction and functional annotation database with a wiki interface
Xiaowei Wang
RNA (2008)
Upstream signalling inhibition enhances rapamycin effect on growth of kidney cancer cells
Luciano J. Costa et al.
UROLOGY (2007)
Identification of the genes for kidney cancer: Opportunity for disease-specific targeted therapeutics
W. Marston Linehan et al.
CLINICAL CANCER RESEARCH (2007)
Mining the Wnt pathway for cancer therapeutics
Nick Barker et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
MEK1/2 inhibition promotes Taxotere® lethality in mammary tumors in vivo
Adly Yacoub et al.
CANCER BIOLOGY & THERAPY (2006)
The !von Hippel-Lindau tumor suppressor gene product represses oncogenic β-catenin signaling in renal carcinoma cells
Benedetta Peruzzi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma
Alexander S. Parker et al.
CANCER (2006)
Targeting the ERK signaling pathway in cancer therapy
M Kohno et al.
ANNALS OF MEDICINE (2006)
Share Paper
